AU2015301726B2 - Production of fully processed and functional Factor X in a furin-secreting mammalian expression system - Google Patents

Production of fully processed and functional Factor X in a furin-secreting mammalian expression system Download PDF

Info

Publication number
AU2015301726B2
AU2015301726B2 AU2015301726A AU2015301726A AU2015301726B2 AU 2015301726 B2 AU2015301726 B2 AU 2015301726B2 AU 2015301726 A AU2015301726 A AU 2015301726A AU 2015301726 A AU2015301726 A AU 2015301726A AU 2015301726 B2 AU2015301726 B2 AU 2015301726B2
Authority
AU
Australia
Prior art keywords
furin
cell
factor
cell line
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015301726A
Other languages
English (en)
Other versions
AU2015301726A1 (en
Inventor
Ernst Bohm
Michael Dockal
Franziska HORLING
Jadranka KOEHN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2015301726A1 publication Critical patent/AU2015301726A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: Baxalta GmbH, BAXALTA INCORPORATED
Application granted granted Critical
Publication of AU2015301726B2 publication Critical patent/AU2015301726B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21075—Furin (3.4.21.75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015301726A 2014-08-12 2015-08-12 Production of fully processed and functional Factor X in a furin-secreting mammalian expression system Active AU2015301726B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462036438P 2014-08-12 2014-08-12
US62/036,438 2014-08-12
PCT/US2015/044883 WO2016025615A1 (en) 2014-08-12 2015-08-12 Production of fully processed and functional factor x in a furin-secreting mammalian expression system

Publications (2)

Publication Number Publication Date
AU2015301726A1 AU2015301726A1 (en) 2017-03-16
AU2015301726B2 true AU2015301726B2 (en) 2021-10-21

Family

ID=54035298

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015301726A Active AU2015301726B2 (en) 2014-08-12 2015-08-12 Production of fully processed and functional Factor X in a furin-secreting mammalian expression system

Country Status (14)

Country Link
US (1) US9873892B2 (enExample)
EP (1) EP3180427B1 (enExample)
JP (1) JP6793114B2 (enExample)
CN (1) CN107002041B (enExample)
AR (1) AR102048A1 (enExample)
AU (1) AU2015301726B2 (enExample)
CA (1) CA2958056C (enExample)
EA (1) EA035444B1 (enExample)
ES (1) ES2742724T3 (enExample)
IL (1) IL250530B (enExample)
MX (1) MX377236B (enExample)
NZ (1) NZ729729A (enExample)
TW (1) TWI666319B (enExample)
WO (1) WO2016025615A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
SG11201912962RA (en) 2017-06-23 2020-01-30 Baxalta Inc Purification of factor viii subspecies
WO2020257942A1 (en) * 2019-06-28 2020-12-30 Peel Sean A F A method for increasing yields and the specific activity of certain recombinant proteins in mammalian cells by co-expressing full-length furin
GB202018320D0 (en) * 2020-11-20 2021-01-06 Univ Newcastle Methods of producing recombinant complement proteins
CN115298204B (zh) * 2022-01-25 2023-04-25 青岛万明赛伯药业有限公司 proNGF突变体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4236698B2 (ja) 1990-11-26 2009-03-11 ジェネティックス インスティチュート，リミテッド ライアビリティ カンパニー 宿主細胞でのｐａｃｅの発現およびその使用法
AT404838B (de) * 1995-11-24 1999-03-25 Immuno Ag Herstellung von proteinen aus pro-proteinen durch fusionsproteine abgeleitet von furin oder furinanalogen
JPH09295945A (ja) * 1996-04-30 1997-11-18 Hoechst Yakuhin Kogyo Kk 成熟型骨誘導因子の製造方法
US5876923A (en) 1996-07-26 1999-03-02 Arch Development Corporation Herpes simplex virus ICP4 as an inhibitor of apoptosis
EP1233986A4 (en) 1999-11-12 2003-01-02 Baxter Biotech Tech Sarl HEMOGLOBIN COMPOSITIONS WITH REDUCED SIDE EFFECTS
US6596526B1 (en) * 2000-06-09 2003-07-22 Baxter Aktiengesellschaft Furin polypeptides with improved characteristics
EP1622928A4 (en) * 2003-05-09 2006-06-14 Res Dev Foundation INSERTION OF FURINE PROTEASE CLEAVAGE SITES IN MEMBRANE PROTEINS AND USES THEREOF
PL1969127T5 (pl) * 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
JP5053435B2 (ja) * 2007-05-18 2012-10-17 バクスター・インターナショナル・インコーポレイテッド Ｖｗｆプロペプチドから成熟ｖｗｆを産生するための方法。
CA2710260C (en) * 2007-12-31 2023-07-11 Barbara Plaimauer Substantially animal protein-free recombinant furin and methods for producing same
KR101544245B1 (ko) 2009-02-03 2015-08-12 아뮤닉스 오퍼레이팅 인코포레이티드 연장된 재조합 폴리펩티드 및 이를 포함하는 조성물
RU2610436C2 (ru) * 2011-06-02 2017-02-10 Баксалта Инкорпорейтед Составы рекомбинантного фурина

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Liu et al., "Improved Expression of Recombinant Human Factor IX by Co-expression of GGCS, VKOR and Furin" 33 Protein Journal 174-183 (2014) *

Also Published As

Publication number Publication date
CN107002041B (zh) 2021-06-29
CA2958056C (en) 2023-07-04
IL250530B (en) 2020-03-31
IL250530A0 (en) 2017-03-30
WO2016025615A1 (en) 2016-02-18
AU2015301726A1 (en) 2017-03-16
EP3180427A1 (en) 2017-06-21
ES2742724T3 (es) 2020-02-17
US20160046957A1 (en) 2016-02-18
TWI666319B (zh) 2019-07-21
AR102048A1 (es) 2017-02-01
US9873892B2 (en) 2018-01-23
JP2017524366A (ja) 2017-08-31
CA2958056A1 (en) 2016-02-18
MX2017001931A (es) 2017-06-30
JP6793114B2 (ja) 2020-12-09
EA201790360A1 (ru) 2017-06-30
EA035444B1 (ru) 2020-06-17
TW201625791A (zh) 2016-07-16
MX377236B (es) 2025-03-07
NZ729729A (en) 2023-07-28
EP3180427B1 (en) 2019-05-22
CN107002041A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
KR102630017B1 (ko) 프로그램화된 사멸 1 리간드 1 (pd-l1) 결합 단백질 및 그의 사용 방법
AU2015301726B2 (en) Production of fully processed and functional Factor X in a furin-secreting mammalian expression system
CN107098969B (zh) 一种治疗hiv感染的嵌合抗原受体的重组基因构建及其应用
CN111089972B (zh) 一种用于检测抗人体髓鞘碱性蛋白抗体的试剂盒及其应用
CN110747198B (zh) 毕赤酵母生产重组人源ⅱ型胶原蛋白单链的方法
CN108103098B (zh) 一种化合物皮肤致敏体外评估细胞模型及其构建方法
US6699686B1 (en) Modified nuclear glucocorticoid receptor, fusion protein, and DNA fragments coding for said receptor and said fusion protein
US20030003536A1 (en) Vanilloid receptor
CN112458058A (zh) 一种过表达traf6的dc细胞、dc细胞疫苗及构建方法和应用
AU2025200285A1 (en) Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
WO1996039178A1 (en) A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
CN112522205B (zh) 一种过表达血管紧张素转换酶2的细胞系及其制备方法与应用
KR20190017363A (ko) 바이오틴을 이용한 단백질의 상호작용체를 확인하는 방법
CN108059675B (zh) 重组pg9-car分子的构建及其在清除hiv-1感染细胞中的应用
CN113355295A (zh) 一种表达人gm-csf的重组溶瘤新城疫病毒及其应用
CN107384917B (zh) mini-gene剪接报告质粒及其构建方法与应用
CN110699380A (zh) 一种ev71病毒核酸质粒及其构建方法及应用
CN108070033A (zh) 一种3bnc-car分子的构建及其在杀灭hiv-1感染细胞中的应用
CN109097392A (zh) 一种基于PiggyBac载体的Her2-CAR-T系统构建方法
US6693226B1 (en) Transgenic mice expressing human p25
CN109957551B (zh) 表达人β-防御素2的重组痘苗病毒及其应用
KR101952102B1 (ko) 단백질 발현량이 증대된 인자 ⅷ 변이체 발현벡터
CN111349653B (zh) 一种人α-乳清蛋白基因定点整合转基因奶牛的制备方法
CN114107384A (zh) 一种靶向人非小细胞肺癌细胞株中eml4-alk融合基因变体1的载体及应用
CN113025651B (zh) 靶向HBV核心启动子的药物筛选细胞模型、Triciribine及结构类似物新应用

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER APPLICANT(S): BAXALTA GMBH; BAXALTA INCORPORATED

FGA Letters patent sealed or granted (standard patent)